Zymergen

Zymergen

Zymergen was established after the 2013 founding of the industrial biotechnology company of the same name, which went public via SPAC in 2021 before being taken private again in 2023 by a consortium led by the founder. The family office manages the wealth generated from that venture, including proceeds from the public offering and subsequent delisting. It is headquartered in Emeryville, California. The office's investment strategy centers on synthetic biology, AI-driven materials discovery, and climate-aligned industrial technologies. It makes direct equity investments in early-stage startups, often leading seed or Series A rounds. Known portfolio companies include the original Zymergen entity, plus co-investments alongside SoftBank and other tech-focused family offices. Geographic focus is primarily North America, with some exposure to European biotech hubs. Team size and additional offices are not publicly disclosed. The office does not publicly maintain a separate philanthropic foundation, though the founding family supports climate and education causes. As of 2025, the office has not announced a recent operational event; the most notable recent activity was the 2023 take-private of the operating company. Zymergen's structural differentiator is its tight integration with the original biotech firm's R&D pipeline. The office sources deals almost exclusively from its own lab discoveries, applying proprietary automation and machine learning tools to identify viable commercial applications. This vertical model is rare among family offices, which typically rely on external GP relationships.